ACNE & KELOID SCARS

ACNE SCARS

Application of regenerative medicine in treatment of acne scars.

The efficacy of a nanofat and plasma rich-platlets injection and fractional CO2 laser resurfacing was evaluated in 30 patients. • The authors showed that the combined approach of nanofat and RegenPRP injection and CO2 laser can improve the appearance of atrophic scars. RegenPRP and nanofat injection also significantly increased skin and subcutaneous tissue thickness.

• Patients reported great satisfaction with the treatment and confirmed the impact of facial acne scars on social life and relationships.

KELOID SCARS

Injecting platelet-rich plasma is an effective and safe method as an adjunctive therapy to resection for treating keloid scars refractory to conventional therapy.

The efficacy of RegenPRP as a treatment of keloid scars was evaluated in 17 patients.7 Evaluations were based on the complete remission of the keloid scars, pruritus severity score and the mean Vancouver Scar Scale (VSS) score, two years after treatment with RegenPRP.

• 53% of keloid scars completely resolved at 2 years, and only 29% relapsed following RegenPRP treatment.

• Pruritus severity score was significantly lower at 2 years compared with baseline Pruritus symptom associated with keloid scar disappeared in 60% of patients.

• The VSS score, which assesses 4 variables: vascularity, height/thickness, pliability, and pigmentation, was significantly improved at the 2 year follow-up (p < 0.001) and had improved in 88% of patients.

REFERENCE

6 Tenna, S., et al., Comparative Study Using Autologous Fat Grafts Plus Platelet-Rich Plasma With or Without Fractional CO2 Laser Resurfacing in Treatment of Acne Scars: Analysis of Outcomes and Satisfaction With FACE-Q. Aesthetic Plast Surg, 2017. 41(3): p. 661-666.

7 Hersant, B., et al., Efficacy of Autologous Platelet Concentrates as Adjuvant Therapy to Surgical Excision in the Treatment of Keloid Scars Refractory to Conventional Treatments: A Pilot Prospective Study. Ann Plast Surg, 2018. 81(2): p. 170-175.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

Hyaluronic Acid

Coming Soon

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EC-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.